​

Aurinia Pharmaceuticals Stock (NASDAQ:AUPH)

ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$15.88

52W Range

$6.55 - $16.48

50D Avg

$13.76

200D Avg

$10.42

Market Cap

$2.09B

Avg Vol (3M)

$1.77M

Beta

1.44

Div Yield

-

AUPH Company Profile

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

CA

Employees

130

IPO Date

Sep 03, 2014

Website

AUPH Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/ServiceDec 24Dec 23Dec 22
License, Collaboration and Royalty Revenue$18.95M$16.98M-
Product$216.19M$158.53M$103.47M
License--$30.56M

Fiscal year ends in Dec 24 | Currency in USD

AUPH Financial Summary

Dec 24Dec 23Dec 22
Revenue$235.13M$175.51M$134.03M
Operating Income$-4.69M$-91.69M$-111.47M
Net Income$5.75M$-78.02M$-108.18M
EBITDA$-4.69M$-63.05M$-103.65M
Basic EPS$0.04$-0.54$-0.76
Diluted EPS$0.04$-0.54$-0.76

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q3 25Nov 04, 25 | 8:30 AM
Q2 25Jul 31, 25 | 8:30 AM
Q1 25May 12, 25 | 8:30 AM

Peer Comparison

TickerCompany
NUVBNuvation Bio Inc.
ABCLAbCellera Biologics Inc.
IMCRImmunocore Holdings plc
BHVNBiohaven Ltd.
STOKStoke Therapeutics, Inc.
CLDXCelldex Therapeutics, Inc.
VERAVera Therapeutics, Inc.
MNKDMannKind Corporation
JANXJanux Therapeutics, Inc.
HRMYHarmony Biosciences Holdings, Inc.